QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
QuidelOrtho (NASDAQ: QDEL) and BÜHLMANN Laboratories AG have announced the integration of two key diagnostic assays on VITROS Systems: the fCAL turbo for inflammatory bowel disease (IBD) detection and fPELA turbo for pancreatic insufficiency diagnosis.
The assays feature rapid results delivery in under 10 minutes, wide reportable ranges, and 90-day analyzer stability. Both tests utilize BÜHLMANN's innovative CALEX Cap technology for simplified sample extraction and are available on VITROS XT 7600, 5600 Integrated System, and 4600 Chemistry Systems.
This partnership aims to enhance non-invasive diagnostic capabilities while reducing healthcare costs and the need for invasive procedures in gastrointestinal and pancreatic health diagnostics.
QuidelOrtho (NASDAQ: QDEL) e BÜHLMANN Laboratories AG hanno annunciato l'integrazione di due importanti test diagnostici sui Sistemi VITROS: il fCAL turbo per la rilevazione della malattia infiammatoria intestinale (IBD) e il fPELA turbo per la diagnosi dell'insufficienza pancreatica.
I test garantiscono risultati rapidi in meno di 10 minuti, ampi intervalli di rilevamento e stabilità dell'analizzatore fino a 90 giorni. Entrambi utilizzano l'innovativa CALEX Cap technology di BÜHLMANN per una semplice estrazione del campione e sono disponibili sui sistemi VITROS XT 7600, 5600 Integrated System e 4600 Chemistry Systems.
Questa collaborazione mira a migliorare le capacità diagnostiche non invasive, riducendo al contempo i costi sanitari e la necessità di procedure invasive nella diagnostica gastrointestinale e pancreatica.
QuidelOrtho (NASDAQ: QDEL) y BÜHLMANN Laboratories AG han anunciado la integración de dos pruebas diagnósticas clave en los Sistemas VITROS: el fCAL turbo para la detección de la enfermedad inflamatoria intestinal (EII) y el fPELA turbo para el diagnóstico de insuficiencia pancreática.
Las pruebas ofrecen resultados rápidos en menos de 10 minutos, amplios rangos reportables y estabilidad del analizador durante 90 días. Ambas utilizan la innovadora CALEX Cap technology de BÜHLMANN para una extracción simplificada de muestras y están disponibles en los sistemas VITROS XT 7600, 5600 Integrated System y 4600 Chemistry Systems.
Esta colaboración busca mejorar las capacidades diagnósticas no invasivas mientras reduce los costos de atención médica y la necesidad de procedimientos invasivos en el diagnóstico gastrointestinal y pancreático.
QuidelOrtho (NASDAQ: QDEL)와 BÜHLMANN Laboratories AG는 VITROS 시스템에 두 가지 주요 진단 검사인 염증성 장질환(IBD) 검사용 fCAL turbo와 췌장 기능 부전 진단용 fPELA turbo를 통합했다고 발표했습니다.
이 검사들은 10분 이내에 신속한 결과를 제공하며, 넓은 보고 가능 범위와 90일간의 분석기 안정성을 자랑합니다. 두 검사 모두 BÜHLMANN의 혁신적인 CALEX Cap 기술을 활용하여 샘플 추출을 간소화했으며, VITROS XT 7600, 5600 통합 시스템 및 4600 화학 시스템에서 이용 가능합니다.
이번 파트너십은 비침습적 진단 역량을 강화하고, 위장관 및 췌장 건강 진단에서 의료 비용과 침습적 절차의 필요성을 줄이는 것을 목표로 합니다.
QuidelOrtho (NASDAQ : QDEL) et BÜHLMANN Laboratories AG ont annoncé l’intégration de deux tests diagnostiques clés sur les systèmes VITROS : le fCAL turbo pour la détection des maladies inflammatoires de l’intestin (MII) et le fPELA turbo pour le diagnostic de l’insuffisance pancréatique.
Ces tests offrent des résultats rapides en moins de 10 minutes, de larges plages de mesure et une stabilité de l’analyseur de 90 jours. Tous deux utilisent la technologie innovante CALEX Cap de BÜHLMANN pour une extraction simplifiée des échantillons et sont disponibles sur les systèmes VITROS XT 7600, 5600 Integrated System et 4600 Chemistry Systems.
Ce partenariat vise à renforcer les capacités de diagnostic non invasif tout en réduisant les coûts de santé et le recours aux procédures invasives dans le diagnostic gastro-intestinal et pancréatique.
QuidelOrtho (NASDAQ: QDEL) und BÜHLMANN Laboratories AG haben die Integration von zwei wichtigen diagnostischen Tests in die VITROS-Systeme angekündigt: den fCAL turbo zur Erkennung von entzündlichen Darmerkrankungen (IBD) und den fPELA turbo zur Diagnose von Pankreasinsuffizienz.
Die Tests liefern schnelle Ergebnisse in unter 10 Minuten, verfügen über einen großen messbaren Bereich und eine Analysator-Stabilität von 90 Tagen. Beide Tests nutzen die innovative CALEX Cap Technologie von BÜHLMANN zur vereinfachten Probenextraktion und sind auf den VITROS XT 7600, 5600 Integrated System und 4600 Chemistry Systems verfügbar.
Diese Partnerschaft zielt darauf ab, die nicht-invasiven Diagnosemöglichkeiten zu verbessern und gleichzeitig die Gesundheitskosten sowie den Bedarf an invasiven Verfahren in der gastroenterologischen und pankreatologischen Diagnostik zu senken.
- Integration of two advanced diagnostic assays (fCAL and fPELA) expanding VITROS Systems capabilities
- Rapid test results in less than 10 minutes improving operational efficiency
- 90-day on-analyzer stability reducing maintenance requirements
- Non-invasive testing method potentially reducing healthcare costs
- None.
Insights
QuidelOrtho's partnership with BÜHLMANN brings valuable non-invasive GI diagnostic tests to its VITROS platforms, expanding clinical offerings and market reach.
QuidelOrtho's integration of BÜHLMANN's fCAL turbo and fPELA turbo assays onto their VITROS Systems represents a significant enhancement to their diagnostic portfolio. These non-invasive stool tests address critical clinical needs: fCAL turbo helps differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS), while fPELA turbo aids in diagnosing pancreatic insufficiency. Both conditions traditionally required more invasive or less precise diagnostic methods.
The technical specifications reveal impressive performance metrics - results in under 10 minutes, wide reportable ranges, and 90-day on-analyzer stability. These features translate to meaningful clinical and operational benefits for laboratories. The compatibility with VITROS Automation Solutions and the CALEX Cap technology simplifies workflow and sample handling, addressing key pain points in stool sample processing.
From a market perspective, these assays align perfectly with several healthcare trends: the shift toward non-invasive diagnostics, demand for cost-effective solutions that reduce dependence on colonoscopies and other invasive procedures, and growing recognition of gastrointestinal health's systemic impact. By enabling earlier, more accurate diagnosis of IBD and pancreatic issues, these tests can significantly improve patient management pathways and potentially reduce healthcare costs.
This partnership demonstrates QuidelOrtho's strategic focus on expanding their diagnostic capabilities through collaborative approaches rather than solely internal development. The MicroTip Partnership Assay (MPA) model allows them to rapidly incorporate specialized tests from leaders in specific diagnostic niches like BÜHLMANN, enhancing the value proposition of their VITROS platforms for clinical laboratories seeking consolidated testing solutions.
Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms
This collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools, the demand for cost-effective healthcare solutions, and the growing focus on gastrointestinal and pancreatic health and its systemic impact. The fCAL and fPELA turbo assays exemplify innovation in diagnostics technology, supporting the shift toward tailored medicine and preventive healthcare.
The fCAL and fPELA turbo assays are both now available for use on QuidelOrtho's VITROS Systems (fCAL turbo and fPELA turbo assays –
Key features include:
- Rapid results in less than 10 minutes
- Wide reportable ranges
- 90-day on-analyzer stability
- Compatibility with VITROS Automation Solutions
- Simplified sample extraction and preparation with CALEX® Cap technology
"The integration of BÜHLMANN's fCAL and fPELA turbo assays with our VITROS Systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses," said Jonathan Siegrist, PhD, Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho. "This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues. With features like the long calibration interval and the ability to use the CALEX Cap–prepared stool samples directly, we're offering a solution that combines clinical accuracy with operational efficiency, ultimately improving patient care."
These assays contribute to better management of gastrointestinal health, reducing the need for invasive procedures and lowering long-term healthcare costs.
Both assays utilize BÜHLMANN's innovative CALEX Cap technology, which simplifies sample extraction and preparation while facilitating safe handling – all seamlessly integrated onto a single VITROS System.
"We are thrilled to collaborate with QuidelOrtho to expand the delivery of an efficient, automated solution for fecal biomarker testing," said Christian Eberle, Chief Executive Officer at BÜHLMANN Laboratories AG. "Our assays, combined with the CALEX Cap stool preparation device, optimize stool extraction efficiency to help maximize stability and yield, resulting in robust fecal calprotectin and pancreatic elastase test results. This collaboration between QuidelOrtho and BÜHLMANN Laboratories AG meets evolving patient and provider needs in the era of personalized medicine and preventive healthcare, offering innovative solutions that align with the industry's focus on non-invasive, cost-effective, and patient-centric diagnostic tools."
The fCAL and fPELA turbo assays' integration with VITROS Systems offers laboratories an efficient workflow for a wide variety of sample collection methods, enhancing flexibility in sample handling and processing.
*CALEX, fCAL and fPELA are trademarks of BÜHLMANN Laboratories AG and VITROS and MicroTip are trademarks of QuidelOrtho.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
About BÜHLMANN Laboratories AG
BÜHLMANN Laboratories AG has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976).
About BUHLMANN Diagnostics Corp (BDC)
As
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-and-buhlmann-laboratories-ag-announce-availability-of-fecal-calprotectin-fcal-turbo-and-fecal-pancreatic-elastase-fpela-turbo-assays-on-vitros-systems-as-a-microtip-partnership-assay-mpa-302503588.html
SOURCE QuidelOrtho Corporation
FAQ
What are the new diagnostic tests announced by QuidelOrtho (QDEL) and BÜHLMANN?
What are the key features of QuidelOrtho's new fCAL and fPELA turbo assays?
Which VITROS Systems are compatible with the new QuidelOrtho diagnostic assays?
How does the CALEX Cap technology benefit QuidelOrtho's new diagnostic tests?
What medical conditions can QuidelOrtho's new diagnostic assays help diagnose?
